Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study — Susan Abushakra (ALZHEON, INC.)
Project Summary There is an urgent need for agents that slow or arrest the progressive course of AD. BAN2401 and aducanumab, antibodies partially targeting soluble Aβ oligomers, have shown efficacy in
| Project title | Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study |
|---|---|
| Project number | 5R01AG065253-04 |
| PI name | Susan Abushakra |
| Institution | ALZHEON, INC. |
| Funding mechanism | R01 |
| Agency | NIA |
| Award amount | $6.50M |
| Fiscal year | 2023 |
| Project start | 2020-08-15T00:00:00 |
| Project end | 2025-05-31T00:00:00 |
| Abstract | Project Summary There is an urgent need for agents that slow or arrest the progressive course of AD. BAN2401 and aducanumab, antibodies partially targeting soluble Aβ oligomers, have shown efficacy in |
| Key terms | <AD dementia><APOE e4><APOE-ε4><APOEε4><Aducanumab><Adverse Experience><Adverse event><Alleles><Alle |
$799/mo
Try GrantRadar →